For example, it has been reported that among patients with melanoma, rapid clinical responses to anti-PD1 immunotherapies were correlated with recruitment of exhausted CD8+ T cells in the tumor at three weeks [62]. This evidence concerns the gene PDCD1 and neoplasm.